BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Badoual C, Combe P, Gey A, Granier C, Roussel H, De Guillebon E, Oudard S, Tartour E. [PD-1 and PDL-1 expression in cancer: significance and prognostic value]. Med Sci (Paris). 2013;29:570-572. [PMID: 23859507 DOI: 10.1051/medsci/2013296005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
Number Citing Articles
1 Guillebon E, Roussille P, Frouin E, Tougeron D. Anti program death-1/anti program death-ligand 1 in digestive cancers. World J Gastrointest Oncol 2015; 7(8): 95-101 [PMID: 26306141 DOI: 10.4251/wjgo.v7.i8.95] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 40] [Article Influence: 5.1] [Reference Citation Analysis]
2 Berahovich R, Liu X, Zhou H, Tsadik E, Xu S, Golubovskaya V, Wu L. Hypoxia Selectively Impairs CAR-T Cells In Vitro. Cancers (Basel) 2019;11:E602. [PMID: 31052261 DOI: 10.3390/cancers11050602] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
3 Combe P, de Guillebon E, Thibault C, Granier C, Tartour E, Oudard S. Trial Watch: Therapeutic vaccines in metastatic renal cell carcinoma. Oncoimmunology 2015;4:e1001236. [PMID: 26155388 DOI: 10.1080/2162402X.2014.1001236] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
4 Granier C, Gey A, Dariane C, Mejean A, Timsit MO, Blanc C, Verkarre V, Radulescu C, Fabre E, Vano Y, Oudard S, Badoual C, Tartour É. [Tim-3: a novel biomarker and therapeutic target in oncology]. Med Sci (Paris) 2018;34:231-7. [PMID: 29547109 DOI: 10.1051/medsci/20183403011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Huang J, Liang H, Zhang X, Xie Z, Jin T. Synergistic antitumor activity of pro-apoptotic agent PAC-1 with cisplatinum by the activation of CASP3 in pulmonary adenocarcinoma cell line H1299: Synergistic activity of PAC-1 and cisplatin. Asia-Pac J Clin Oncol 2016;12:41-51. [DOI: 10.1111/ajco.12419] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
6 Zheng Y, Yang Y, Wu S, Zhu Y, Tang X, Liu X. Combining MPDL3280A with adoptive cell immunotherapy exerts better antitumor effects against cervical cancer. Bioengineered 2017;8:367-73. [PMID: 27754760 DOI: 10.1080/21655979.2016.1230573] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]